How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

IK

NASDAQ:IKT
Get a brief AI stock analysisSaves ~ 15 minutes of your time

IK

Inhibikase Therapeutics IncNASDAQ IKT Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is IKT undervalued compared to its fair value?

The fair value of IKT stock is hidden USD. Relative to the market price of 1.48 USD Inhibikase Therapeutics Inc is hidden.

Inhibikase Therapeutics, Inc. provides infectious disease treatments. The company is headquartered in Atlanta, Georgia and currently employs 6 full-time employees. The company went IPO on 2020-12-23. The firm is focused ...[More about valuation]

Inhibikase Therapeutics Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.011 $B

Price:

1.48 USD

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.733

FINANCIALS

Inhibikase Therapeutics financial for reporting period

Income Statement


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0048 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0047 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

Balance Sheet

0.011 B
0.0068 B

Financial Position Analysis

Assets

0.011 B
Current Assets
0.011 B
Total non-current assets
0.0003 B

Total current liabilities
0.0042 B
Total non-current liabilities
0.0001 B

Cash Flow Statement

-0.0039 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.0039 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Inhibikase Therapeutics fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-147 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-117 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is IKT attractive for investment based on fundamental analysis?

IKT stock rating is hidden. Inhibikase Therapeutics is a hidden by Eyestock methodology.

Get IKT Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-9 604

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

4.912

Debt / Equity ratio:

ROE:

-147

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

IKT analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for IKT to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Inhibikase Therapeutics Inc competitors

AB

ABBV

Abbvie Inc

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Ill...

Discover

AM

AMGN

Amgen Inc

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company...

Discover

VR

VRTX

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs fo...

Discover

Inhibikase Therapeutics Inc dividends

IKT dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About IKT stock

About the company Inhibikase Therapeutics Inc

Market cap $B

0.011

Dividend yield

Shares outstanding

28.0278 B

Inhibikase Therapeutics, Inc. provides infectious disease treatments. The company is headquartered in Atlanta, Georgia and currently employs 6 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The firm's product candidates include IkT-148009, IkT-001Pro and IKT-01427. Its lead product candidate, IkT-148009 is a brain penetrant Abelson tyrosine kinase (c-Abl) inhibitor, that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the gastrointestinal (GI) tract. Its IkT-148009 is for the treatment of PD, including its manifestation in the GI tract. Its product candidate IkT-001Pro, is a prodrug of the anticancer agent Imatinibm, which is used as a treatment for chronic myelogenous leukemia (CML). IkT-01427 is an oral, brain-penetrant medication, designed to block the entry of the John Cunningham (JC) virus into the cell, thereby preventing the virus’ ability to replicate in the body.

IKT profile

  • Ticker

    IKT

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    23 December 2020

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    6

  • City

    Atlanta

  • Address

    3350 Riverwood Parkway Se, Suite 1900

  • Cusip

    45719W106